Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
- Author
- ReachMD
- Published
- Fri 06 Jun 2025
- Episode Link
- http://reachmd.com/programs/cme/nonsteroidal-mra-sglt2i-in-people-with-ckd-t2d-current-evidence-and-rationale-for-combination-therapy/29909/
CME credits: 0.25
Valid until: 06-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/nonsteroidal-mra-sglt2i-in-people-with-ckd-t2d-current-evidence-and-rationale-for-combination-therapy/29909/
Valid until: 06-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/nonsteroidal-mra-sglt2i-in-people-with-ckd-t2d-current-evidence-and-rationale-for-combination-therapy/29909/
Can combining a nonsteroidal MRA and an SGLT2 inhibitor unlock new clinical potential for patients with type 2 diabetes and chronic kidney disease (CKD)? In this expert discussion, Dr. Jennifer Green and Dr. Hiddo Heerspink review the latest findings from the CONFIDENCE trial, which demonstrated a significant additive reduction in albuminuria—an important surrogate marker for kidney and cardiovascular risk—when finerenone and empagliflozin are used together. They explore the clinical rationale behind combination therapy, address persistent challenges in CKD detection, and consider the practical implications for implementing these therapies in high-risk populations.
=